Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Feasibility of sirolimus and tacrolimus-coated silicone plate to modify conjunctival wound healing in the rabbit model

Search Title by author or title

Session Details

Session Title: Inflammation and Pathology

Session Date/Time: Sunday 11/09/2016 | 14:30-16:00

Paper Time: 15:48

Venue: Hall C2

First Author: : S.Yun SOUTH KOREA

Co Author(s): :    M. Kim   H. Tchah   J. Kim              

Abstract Details

Purpose:

To show the feasibility of sirolimus and tacrolimus-coated silicone plate to modify conjunctival wound healing in the rabbit model

Setting:

Asan Medical Center, Ulsan University, Seoul, Republic of Korea

Methods:

Twenty five rabbits were involved and randomly divided into 5 groups. Limbus-based peritomy was made at superior cornea and normal saline (NS group), mitomycin-C (MMC group), sirolimus (SR group), tacrolimus (TC group) and 10% ethanol (ET group)-coated silicone plate was inserted at sub-Tenon space in each group. Conjunctival congestion was evaluated at 1 and 4 weeks postoperatively. At 4 weeks, inflammatory cell, fibroblast, myofibroblast, blood vessel, and goblet cell were counted in the conjunctiva and Tenon’s capsule around silicone plate.

Results:

Conjunctival congestion was significantly reduced at 4 weeks than that at 1 week in all groups (P<0.05). Conjunctiva was significantly less congested in the TC group than in the other groups at 1 week and 4 weeks (P<0.05). The MMC group had the least goblet cell among all groups. The TC and SR groups had less inflammatory cell and fibroblast than the other group and no less goblet cell than NS and ET groups.

Conclusions:

Sirolimus and tacrolimus-coated silicone plate was feasible to inhibit inflammation and fibrosis as an alternative of mitomycin C in the rabbit model.

Financial Disclosure:

NONE

Back to previous